← Eichor
Condition: Gc Gejc Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Gc Gejc

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC
Phase 3 · 1 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT04342910Lenvatinib Plus Tislelizumab and CapeOX as First-Line Treatment for Advanced GC/GEJC With Positive PD-L1 and Low TMEscor
Phase 2 · 1 location(s) · Nanfang Hospital, Southern Medical University · NCT06157996Disitamab Vedotin Combined With SOX Regimen Versus SOX Alone as Adjuvant Therapy for HER2-Moderate/High Expressing Stage
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07474324XELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC
Phase 1/Phase 2 · 2 location(s) · West China Hospital · NCT06742411A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Posit
Phase 3 · 1 location(s) · Sichuan Baili Pharmaceutical Co., Ltd. · NCT07518147A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alon
Phase 1/Phase 2 · 67 location(s) · BioNTech SE · NCT07070232A Phase II Trial of Perioperative Adebrelimab Combined With XELOX in Resectable Locally Advanced Gastric/Gastroesophagea
Phase 2 · 1 location(s) · Tianjin Medical University Cancer Institute and Hospital · NCT06506292
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.